Board of Directors

Nissim Darvish, MD, PhD

Board Chairman

Nissim Darvish is a General Partner at MeOhr Ventures, a venture capital fund, and serves as a director of several private companies. Previously, he was a Venture Partner at OrbiMed Israel and a member of the boards of directors of 9 Meters Biopharma and Medigus. Earlier, Dr. Darvish was a General Partner managing life sciences investments at Pitango Venture Capital. He was also a founder and CEO of Impulse Dynamics, where he oversaw several financing rounds and $250 million in transactions. Dr. Darvish obtained his MD and PhD in biophysics and physiology from the Technion in Israel and subsequently conducted post-doctoral research at the U.S. National Institutes of Health. He has published over 100 patents and authored more than 20 scientific publications.

• 

  Chair
  Compensation Committee
• 

  Member
  Audit Committee
• 

  Member
  Corporate Governance & Nominating Committee

Neil Cohen

Director

Neil Cohen served as interim CEO of Anchiano Therapeutics from October 2020 until its merger with Chemomab in March 2021. He has served as the Chairman and Chief Executive Officer of Castel Partners Ltd. since January 2012. In 1994, he co-founded Israel Seed Partners, a leading venture capital firm, and managed the firm until 2019. Mr. Cohen has invested in and served on the boards of directors of many private technology companies, including a number that were acquired or completed successful initial public offerings. He is a venture partner at SKY, an Israeli middle-market private equity firm, at Hetz Ventures Management Ltd., an early-stage Israeli venture capital fund, and Shavit Capital. Mr. Cohen was previously the Business Editor of The Jerusalem Post and began his career in the private equity group at the Rothschild Bioscience Unit of N M Rothschild & Sons Limited in London. Mr. Cohen received a BA and MA, with first class honors, from Oxford University.

• 

  Chair
  Audit Committee
• 

  Member
  Compensation Committee

Gwen Melincoff

Director

Ms. Melincoff has over 25 years of leadership experience in the biotechnology and pharmaceutical industries. Her experience has spanned public and private company boards, venture financing, business development, licensing, mergers and acquisitions, research operations, marketing, product management and project management.

Ms. Melincoff currently sits on the board of directors of Protalix Biotherapeutics and Gain Therapeutics. She previously served on the board at Collegium Pharmaceutical, Soleno Therapeutics, Photocure ASA and Tobira Therapeutics.

She served as Vice President of Business Development at BTG International Inc. a UK- specialist healthcare company from 2014-2016. Prior to that Ms. Melincoff was Senior Vice President of Business Development at Shire Pharmaceuticals from 2004-2013. Additionally, she led the Strategic Investment Group (SIG), Shire’s $50MM corporate venture fund which was started in 2010. She served as a board member/board observer at DBV Technologies, AM Pharma, ArmaGen Technologies, Promethera Biosciences, Naurex Inc. (acquired by Allergan) and Enterome. During her tenure, she was involved in numerous licenses, product divestments, co-promotion and collaboration agreements, and mergers and acquisitions. She was responsible for the collaboration with New River Pharmaceuticals that led to the $2.6 billion acquisition of the company. Ms. Melincoff was named a “Top Women in Biotech 2013” by Fierce Biotech as well as being named to the Powerlist 100 of Corporate Venture Capital in 2012 and 2013.

Prior to joining Shire, Ms. Melincoff was Vice President of Business Development at Adolor Corporation, a biopharmaceutical company focused on the development of pain management products that was acquired by Cubist Pharmaceuticals and then Merck.

Ms. Melincoff worked for Eastman Kodak for over ten years in a number of their health care companies, including Eastman Pharmaceuticals which acquired Sterling Drug. She was the Director of Business Development at NanoSystems, a spin-out from Kodak that specialized in nanotechnology drug delivery that was acquired by Elan.

Ms. Melincoff has a B.S in Biology, a Master’s of Science in Management, and has attained the designation of the Certified Licensing Professional (CLP™).

• 

  Chair
  Corporate Governance & Nominating Committee

Adi Mor, PhD

Director

Dr. Mor, Chief Executive Officer and Chief Scientific Officer of Chemomab,  co-founded Chemomab in 2011. She has extensive knowledge and experience in immunology focusing on autoimmune and inflammatory diseases and broad experience in designing, promoting and patenting a novel class of monoclonal antibodies to treat inflammatory and fibrotic diseases. Dr. Mor earned her PhD in immunology from Tel Aviv University in the Department of Neurobiochemistry and is the lead author of numerous scientific journal publications in immunology and inflammatory disorders.

Alan Moses, MD

Director

Alan Moses spent 14 years at Novo Nordisk, held multiple roles and rising to the position of Senior Vice President and Global Chief Medical Officer. Dr. Moses was co-founder and co-director of the Clinical Investigator Training Program at Beth Israel Deaconess-Harvard Medical School-MIT and served as Senior Vice President and Chief Medical Officer of the Joslin Diabetes Center in Boston and was appointed Professor of Medicine at Harvard Medical School. Dr. Moses earned his MD from the Washington University School of Medicine in St. Louis, worked at the National Institutes of Health and completed subspecialty clinical training in Endocrinology at Tufts New England Medical Center.

• 

  Member
  Audit Committee